Furthermore, we assessed the potential of serum PDZD11 as a clinical diagnostic marker by enrolling a cohort comprising 78 HCC patients and 62 healthy controls (HC) using the ELISA analysis and combining its expression with common tumor markers.<h4>Results</h4>Our research found significantly higher PDZD11 mRNA expression in HCC tissues compared to tumor-adjacent tissues (<i>p</i> < 0.001), which was associated with lower overall survival (OS) rates (<i>p</i> < 0.01). Here, PDZD11 is linked to hepatocellular carcinoma.